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Introduction – Sarcoidosis-associated fatigue (SAF) is a common clinical problem with 
limited treatment options. This study was undertaken to determine the feasibility of 
performing a definitive trial to determine the clinical efficacy methylphenidate in SAF. 
Methods – This was a parallel-arm, double-blind, placebo-controlled randomised-controlled 
feasibility trial enrolling sarcoidosis patients reporting significant fatigue. Patients with a 
Fatigue Assessment Scale score of more than 21 were randomised to receive up to either 
10mg twice daily methylphenidate or identical placebo capsules twice daily, in a dose 
escalation fashion, for up to 24 weeks. Outcomes included number of participants eligible 
and willing to participate, withdrawal rates, adherence rates and ability to maintain 
blinding. 
Results – Of 385 patients screened, 56 (14.5%) were eligible and 23 (41% of eligible 
patients) were randomised. No withdrawals occurred. One participant in the 
methylphenidate arm discontinued study medications due to chest pain. The side effect 
profile was not different between the groups. Median medication adherence rates were 
98% and 99% in the methylphenidate and placebo arms respectively. A greater proportion 
of participants receiving methylphenidate predicted their allocated treatment whilst blinded 
compared with those receiving placebo (93.3% vs 57.1%). The investigator could not predict 
the treatment allocation. Both groups showed clinically meaningful improvements in fatigue 
from baseline, although no between-group difference was seen. 
Conclusions –The data supports the feasibility of performing a double-blind parallel trial 
powered to determine the clinical efficacy of methylphenidate for SAF, however a 
multicentre study will be required.. 
Trial Registration – Clinicaltrials.gov NCT02643732 
 




What is the key question? – Is it feasible to attempt a full-size randomised-controlled trial of 
neurostimulants for sarcoidosis-associated fatigue and what should that trial look like? 
  
What is the bottom line? – Methylphenidate appeared safe and well tolerated overall. Recruitment 
was such that a multi-centre study is required and would be improved by some adjustments to study 
design and follow-up. 
  
Why read on – The FaST-MP study provides important data when considering future randomised 






Sarcoidosis, a multi-system granulomatous disease, is frequently complicated by 
constitutional symptoms including fatigue(1) which can be chronic and difficult to 
manage(2), with significant impairment of quality of life(1). Whilst several treatments have 
been investigated(3), many are systemic immunosuppressant therapies associated with 
significant side-effects or costs, and may not be appropriate in cases where sarcoidosis-
associated fatigue (SAF) is the sole clinical manifestation of sarcoidosis.  
 
Methylphenidate and its d-isomer dexmethylphenidate are piperidine-class stimulants 
which amplify dopaminergic neurotransmission in the basal ganglia(4). These drugs have 
been trialled for significant fatigue in other clinical scenarios, although the evidence for 
clinical efficacy has been mixed. In a placebo-controlled, double-blind trial in post-
chemotherapy participants with fatigue, dexmethylphenidate exhibited a clinically 
significant reduction in fatigue(5). A Cochrane review of treatments for cancer-related 
fatigue from five randomised controlled trials (RCTs) concluded that “the current evidence 
supports the use of psychostimulants in cancer-related fatigue”(6). A trial of  
methylphenidate in 109 human immunodeficiency virus positive patients improved fatigue 
with methylphenidate, with 41% of participants receiving the drug demonstrating a greater 
than 50% improvement in visual analogue scale fatigue scores over a 6-week period(7). In 
contrast, no difference between methylphenidate and placebo was seen in a cohort of 68 
fatigued patients followed over a 12-week period who had received radiotherapy for brain 
tumours(8). In chronic fatigue syndrome, a cross-over study of 60 patients found that only 
17% reported improvements in fatigue scores over a 4-week duration(9). 
 
In SAF, the d-isomer of methylphenidate (dexmethylphenidate) has been trialled in a small 
cross-over study involving ten patients and showed evidence of reduced fatigue over an 8-
week period(5). However, questions remain regarding the feasibility of performing an 
appropriately powered trial to determine the clinical efficacy of methylphenidate for SAF. 
The proportion of patients with sarcoidosis eligible for such a trial is unknown. Sustainability 
of treatment effect beyond 8-weeks in SAF is unknown. Furthermore, the use of a cross-
over design, used in previous studies investigating neurostimulants for SAF(5, 10), has been 
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suggested as inappropriate for these medications due to the risk of unblinding due to 
apparent treatment effects(11). This may lead to an increased observed effect size for 
stimulant medications, as shown in cross-over studies investigating their use in other 
conditions(12).  
 
The objective of the FaST-MP study was to determine the feasibility of performing a large-
scale trial of methylphenidate for treatment of sarcoidosis-associated fatigue. Clinical data 





Study design and setting 
 
The full study protocol has been previously published (13). This was a parallel-arm, 
randomised, double-blind, placebo-controlled feasibility trial with participants allocated to 
methylphenidate or matched placebo on a 3:2 ratio. Participants were identified by 
screening the medical notes for reference to “fatigue” in patients with sarcoidosis under 
active follow-up by the respiratory clinic at the Norfolk and Norwich University Hospital 
(NNUH), Norwich, UK, or identified at participant identification centres (PICs) in East Anglia 
and referred to the trial team at NNUH. The trial was supported by the Norwich Clinical 
Trials Unit (NCTU) based at the University of East Anglia (UEA). 
 
Participants received methylphenidate or an identical placebo for up to 24 weeks. 
Measurements of safety and efficacy were performed throughout the study and six weeks 
after completing study medications. After completing study medications but prior to study 
unblinding participants were offered the opportunity to participate in moderated focus 
groups to discuss their experience of the study. A protocol amendment was approved in 





Patients were eligible if they had a diagnosis of sarcoidosis, stable disease and significant 
fatigue (Fatigue Assessment Scale (FAS) score of greater than 21 points on two occasions 
two-weeks apart prior to starting medication, the average value used as the baseline value). 
Patients were excluded if they had an alternative cause for their fatigue, including anaemia, 
hypercalcaemia, thyroid dysfunction or obstructive sleep apnoea (OSA). All patients were 
screened for symptoms of OSA using the STOP-Bang questionnaire(14); participants scoring 
4 or above, or who had symptoms suggestive of OSA irrespective of the STOP-Bang score, 
underwent overnight oximetry prior to inclusion to exclude OSA. Participants were also 
excluded if they were receiving medication known to interact with methylphenidate, or had 
risk factors for adverse events including previous cardiovascular events, seizures, thyroid 
disorders, glaucoma or established liver disease. The full list of exclusion criteria is 
available(13). 
 
Potential participants were sent written trial information and then contacted by telephone; 




Research Ethics approval (reference 16/EE/0087) and Clinical Trial Authorisation (EudraCT 
number 2016-000342-60) were gained. The study was registered on clinicaltrials.gov 
(NCT02643732).  
 
Intervention and follow-up 
 
The interventional drug was methylphenidate hydrochloride (Tranquilyn), over-
encapsulated with a gel capsule (Guys and St Thomas’ Pharmacy Manufacturing Unit, 
London, UK); the comparator was an identical placebo capsule.  The initial dose was 10mg 
twice daily of methylphenidate or one identical placebo capsule twice daily, with further 
review at week 2 to increase to 20mg of methylphenidate (as 2 x 10mg) twice daily or two 
identical placebo capsules twice daily, if appropriate.  
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Following their screening visit, eligible participants attended seven face to face study visits 
over a 24-week period (weeks 0, 2, 4, 6, 12, 18 and 24). Between study visits, participants 
were contacted by the study team via phone at weeks 1, 3, 5, 8, 10, 14, 16, 20 and 22 to 
review any potential side effects or safety concerns. Follow-up was truncated for 
participants enrolled after December 2017, who received methylphenidate for a minimum 
of 12 weeks. 
 
Randomisation and data-collection 
 
Randomisation was performed using block randomisation with blocks of five, in a 3:2 ratio 
favouring methylphenidate to capture more data on efficacy and safety of methylphenidate. 
Stratification was performed for baseline fatigue severity (FAS score 22-34 and 35-50). The 
randomisation sequence was produced by the study statistician, with allocation performed 




The FaST-MP study involved patients from conception through to completion. Patients with 
sarcoidosis who had suffered from severe fatigue were involved in the original application 
for funding and drafting of the original protocol. Further input from patients with 
sarcoidosis helped with trial oversight through membership of the trial steering committee. 
Patients and the trial participants were all involved in reviewing of the final results following 




A maximum sample of 30 participants was chosen in line with recommendations for sample 




The primary feasibility outcomes of interest were: 
1. Proportion of patients eligible for trial participation and willing to participate 
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2. Recruitment rate and retention  
3. Number and type of adverse events 
4. Indication of continuation of effect at stable dose during treatment period 
5. Ability to maintain blinding to allocation 
6. Number of missed or unfilled assessments  
7. Number of patients correctly using accelerometers  
8. Acceptability of study visits and assessments 
9. Overall perception of trial involvement 
 
Outcomes 1-7 were measured from quantitative data collected during the study. Outcomes 
8 and 9 were assessed by analysis of the focus group discussion data. 
 
Data was also collected on clinical outcomes for exploratory analysis. Fatigue was measured 
using the FAS(17) and Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-
Fatigue)(18). Anxiety was assessed with the Hospital Anxiety and Depression Scale 
(HADS)(19), with the anxiety (HADS-A) and depression (HADS-D) scores reported separately. 
Exercise capacity was measured using the modified incremental shuttle walk test(20); this 
allows those with minimal cardiopulmonary impairment to be adequately stressed and has 
been shown to strongly correlate with peak VO2 levels when compared with 
cardiopulmonary exercise testing in patients with sarcoidosis(21). Physical activity levels 
captured by a wrist-worn activity monitors (GENEActiv original, ActivInsight; 
Cambridgeshire, UK). The feasibility of repeatedly using these devices was determined by 
evaluating the number of devices safely returned with ‘valid’ data (at least 10 hours wear 
period for at least two weekdays and two weekend days)(22). Assessments of blood 
pressure and pulse, weight, biochemistry (full blood count, urea and electrolytes and liver 
function), electrocardiogram (ECG), and adverse events occurred at each visit. 
 
At the final study visit (week 24, or week 12 or 18 for patients recruited after December 
2017) participants completed an exit questionnaire. This asked if the participant would wish 
to continue the medication if the option were available, if they found participation in the 
study useful and if they would take part in the study given the chance again. It also asked 
the participant to predict whether they had been receiving methylphenidate or placebo; the 
investigator separately completed their prediction of the participant’s allocation. 
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All participants were invited to attend face-to-face moderated, audio-recorded focus groups 
to discuss experiences during the trial, after they had completed medications but prior to 
unblinding. Three focus groups were undertaken, each containing between four and six 
participants. All focus groups were undertaken at the same location (University of East 
Anglia). A pre-specified topic guide was used to facilitate discussion using open-ended 
questions. The two key topics being investigated were the participants’ experience of trial 
participation (both positive and negative) and whether they could suggest any changes to 
the study which might improve the future recruitment or retention of participants in any 
follow-up study to FaST-MP. The full methods for the focus groups are contained in 




Feasibility and safety outcomes were reported as event rates. An exploratory analysis of the 
clinical data was performed on an intention to treat basis, including all participants who 
received study medications at any point. Plots were constructed for each outcome, 
displaying mean scores by allocation group with 95% confidence intervals. Mean differences 
between allocation group were compared using a two-sample t-test (unadjusted analysis), 
with adjusted analysis of the data using a general linear regression model controlling for 
baseline values and initial fatigue severity. Continuation of effect was assessed using 
longitudinal measurements of FAS and FACIT-Fatigue. Any data not displayed or reported 
within this paper is included in the supplementary appendix. Analysis was performed using 




Participants, care providers and investigators were blinded to allocation; the placebo and 
active treatments appeared identical and were dispensed in identical containers. Trial 
pharmacists at the NNUH could identify allocation due to unequal arm size. Pharmacy 
monitoring was performed by an independent member of NCTU to ensure unblinding did 




Screening and recruitment 
 
Recruitment occurred between 07/11/2016 and 02/03/2018; the trial ended because of a 
pre-specified end date. In total 385 patients were screened, of which 379 were under the 
care of NNUH. Including patients referred from PIC sites and after exclusions, 56 patients 
(14.5%) were potentially eligible, of which twenty-three participants agreed to participate 
(41.1% of all eligible patients, 6.0% of all screened patients). At NNUH alone, 52 eligible 
patients were identified (13.7% of NNUH patients); of those, 19 patients (36.5% of eligible 
NNUH patients, 5.0% of all NNUH patients) agreed to participate. Twenty-two participants 
received their allocated intervention; one participant was excluded after randomisation but 
prior to receiving their allocated intervention due to identification of an exclusion factor. 
Recruitment averaged 1.4 participants/month overall (1.2 from NNUH). No participants 
withdrew from the study. Figure 1 shows screening, trial recruitment and flow. 
 
Baseline characteristics of participants who received their allocated intervention are shown 




Adherence and safety 
 
Median adherence was 98% in the methylphenidate arm and 99% in the placebo arm. Only 
one participant had less than 80% adherence. Adherence rates did not change as the study 
progressed. 
 
At the end of the study five participants in the methylphenidate arm were receiving a dose 
of 10mg (1 capsule) twice daily, nine participants were receiving 20mg (2 capsules) twice 
daily and one participant had discontinued the study medication (due to chest pains). All 




Ninety-six adverse events (AEs) were observed, including one serious event attributed to a 
concurrent medication. The number of participants developing at least one AE in each organ 
system is shown in Table 2. No cardiac events, ECG abnormalities or biochemical 
abnormalities requiring discontinuation occurred in any participant. Participants receiving 
methylphenidate had a weight reduction of 2.9kg; no weight change was observed in the 





The proportion of missing data points was 5.0% or less for all outcomes except the modified 
shuttle walk test (MSWT) (11.7% data points missing), which was due to temporary lack of 
access to suitable facilities (Table 3). Activity monitors were worn reliably. Out of 60 wear 




Exploratory clinical efficacy 
 
Baseline mean FAS scores were 35.9 in both arms (standard deviation 7.8). Baseline FACIT-
Fatigue score was 19.9 in the methylphenidate arm and 20.0 in the placebo arm. Changes in 
fatigue scores were similar in both arms (Figure 2). At week 12 and 24 a similar proportion 
of participants in each arm met the minimal clinically important difference for the FAS score 
(73.3% and 80.0% in the methylphenidate arm at weeks 12 and 24 respectively, 71.4% and 
83.3% in the placebo arm). Both groups showed an increase in fatigue six weeks post-
medication.  
 
Mean baseline HADS-A and HADS-D scores were 7.8 and 7.9 respectively for the 
methylphenidate group, 8.0 and 6.6 respectively for the placebo group. Mean HADS-A score 
was 2.5-4.4 points lower in the placebo arm than the methylphenidate arm across the 
medication period. HADS-D scores remained similar throughout the study. Figure 2 shows 






Nineteen participants (12 methylphenidate, 7 placebo) completed the exit questionnaire. A 
greater proportion of participants in the methylphenidate arm wanted to continue the drug 
(91.7%) compared with placebo (71.4%). All participants stated that they found participation 
in the trial useful and would take part if given the chance again. Blinding was maintained in 
the placebo arm but participants receiving methylphenidate were aware of when they 
received the medication; 14 of the methylphenidate group correctly predicted their 
allocation (93.3%), compared with four in the placebo arm (57.1%). The investigator 
predicted allocation to methylphenidate less accurately, correctly predicting the allocation 
of 11 participants in the methylphenidate arm (73.3%, but was slightly better in predicting 
allocation to placebo (5 participants, 71.4%).  
 
Fourteen participants attended post-trial focus groups. Participants talked positively about 
the study and the impact of treatment on their lives; they were keen to see 
methylphenidate available as an option for SAF. The number of questions was considered 
an issue, particularly as there was overlap between some of the questionnaires. It was 
suggested that the fatigue outcome measures used were “vague” and might miss 
improvements that participants felt were important to them, with participants in one of the 
focus groups suggesting simpler but more frequent measures of fatigue, such as a visual 
analogue scale (VAS), might be used alongside a formal questionnaire such as FAS. 
Alternatively, a self-report diary was also suggested. The full focus group outcomes relating 








The outcomes from the FaST-MP study show a phase-III trial is feasible but a multicentre 
study is required and modifications from this trial design will improve deliverability. The trial 
did not meet its recruitment target, in part due to the cautious entry criteria and the 
intensive visit schedule, although retention of participants and adherence to the study 
measurements was excellent. Methylphenidate was safe and well tolerated. Our experience 
with wrist-worn activity monitors suggests that the use of these devices is feasible and 
carries advantages over the use of formal measures of exercise capacity such as MSWT. The 
use of the FAS score should be the primary outcome for any future trial, but could be 
complemented by a visual analogue scale (VAS), with an outcome assessment at 3 months. 
We have shown that a parallel study is appropriate but a cross-over design runs the risk of 
unblinding. 
 
The FaST-MP study had several strengths. This was a mixed-methods study which carefully 
evaluated safety of patients with sarcoidosis receiving methylphenidate. Through screening 
a large number of patients with pulmonary sarcoidosis under active follow-up by a large 
regional hospital it identified the proportion of patients potentially eligible to undertake a 
study such as this, excluding patients with alternative causes for fatigue. Screening of 
fatigue was robust, including measurement of fatigue with a validated score on two 
separate occasions, to ensure participants had fatigue which was both significant and stable.  
It used numerous different end-points. This included the use of wrist-worn activity monitors 
to monitor changes in daily activity was successful and can be replicated in future studies in 
place of departmental exercise tests.  
 
There were limitations to this study. It did not meet its target recruitment number. Whilst 
the proportion of patients screened reporting fatigue was lower than seen in some previous 
studies(23), it is in line with previously reported UK data from the BTS sarcoidosis 
registry(24). The frequent visit schedule deterred some patients and the entry criteria 
excluded a high proportion of patients for reasons of safety which may be relaxed in future 
studies. As a single centre, our recruitment and retention rates may be better than those 
seen in a multi-centre study. The method of screening may have meant some patients with 
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fatigue were missed as the symptom was not reported in their letters. Screening all patients 
with the FAS questionnaire may have identified additional patients, although these patients 
may not have felt fatigue was a significant issue for them and so would not be considered 
for neurostimulants on a clinical basis.  
 
The FAS instrument remains the outcome of choice for measuring fatigue; it has been 
recommended for any study measuring fatigue in patients with sarcoidosis(25). It is 
validated in sarcoidosis (17), has a known minimal clinically important difference(26), and is 
widely used(1). FAS was reliably completed in this study. The changes seen in FAS score 
were mirrored by FACIT-Fatigue, so an alternative fatigue measure added little. Any future 
study should utilise FAS to quantify fatigue. One change suggested by the focus group 
participants was the addition of a simple fatigue visual analogue scale (VAS), which could be 
used alongside FAS on a regular basis, potentially weekly. Whilst fatigue visual analogue 
scales have been used in other conditions such as RA(27) they have not been evaluated in 
sarcoidosis. Therefore, whilst they may provide a useful adjunct to the FAS score, they 
should not replace it in any future study. Discussions in the focus groups suggested that the 
FAS may miss changes in fatigue important to individuals; adding a VAS may help with this.  
 
The experience of using wrist-worn activity monitors suggests that these devices are 
feasible to use within a subsequent trial; the rate of patients returning at least minimum 
valid data were high and comparable to observational studies using posted accelerometer 
devices such as UK Biobank(28). We were able to reliably collect valid data across the trial 
period with only one device lost. The use of these devices is preferable to exercise tests due 
to difficulties with reliably accessing suitable facilities at multiple sites. It also provides data 
directly linking to exercise levels on a daily basis, data that is not provided by a laboratory-
based exercise test. In this study we encountered problems securing space for the MSWT 
which only requires a 10m track; activity monitors would remove this requirement. 
 
Given that the planned recruitment goal was not met, consideration must be given to ways 
of increasing recruitment. Over 20% of potentially eligible participants declined to 
participate due to the number of visits. Reducing the number of study visits is likely to have 
encouraged a greater number of eligible patients to participate. The safety profile of 
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methylphenidate in this study suggests that fewer safety visits are required; no issues with 
blood pressure or pulse were identified during the study and screening for adverse events 
could be done via phone or remote monitoring. Furthermore, the exclusion criteria for FaST-
MP was deliberately risk-averse. Some cases, these restrictions may be relaxed for example 
a number of screened patients (2.5%) were excluded purely due to the use of tricyclic 
antidepressants; these drugs need not be a strict exclusion criterion but could be continued 
with monitoring. Methylphenidate is considered safe in other conditions including in 
children and adults(29), in those with attention deficit hyperactivity disorder(30) and those 
with Alzheimer’s disease(31). 
 
We questioned whether it was possible to undertake a future blinded study of a 
neurostimulant in SAF, given the previous concerns with cross over studies(11). Most 
patients receiving methylphenidate correctly predicted their allocation; neither those in the 
placebo arm nor the investigators were reliably able to. Difficulty maintaining blinding in the 
methylphenidate group suggests it would be challenging to maintain blinding in a cross-over 
study, as previously noted in other studies investigating stimulants(11). In any future study 
it is important that a formal assessment of blinding efficacy should be performed to ensure 
that blinding has not inadvertently been broken. There are a number of methods for doing 
this that can easily be added to the questionnaires delivered during the study and would 
ensure robustness of the outcomes. These include the James’ blinding index (BI) and Bang 
BI, which require participants to express their prediction regarding allocation and the 
degree of certainty with which they make the prediction; these predictions can then be 
statistically compared between groups to determine if blinding has been maintained(32).  
 
Though participants in both arms showed reduced fatigue, the study was not intended to be 
powered for clinical effect. The small sample size makes it difficult to draw conclusions 
about the performance of either arm, though both subjective and objective measures have 
been seen to improve in the placebo arms of trials in other conditions(33). We performed 
multiple baseline fatigue measurements prior to commencing medications given the 
subjective nature of fatigue, in line with previous suggestions(33), though other aspects of 
the trial design may have influenced the outcomes seen in the placebo arm. The high level 
of contact with the study team may have reduced anxiety levels(34, 35); anxiety is known to 
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moderate fatigue(36). Furthermore, because of the small trial team involved, participants 
met the same investigator and support team which may have further influenced this effect. 
Participants may have subconsciously filled a “good participant” role and striving to meet 
the study hypothesis(37). Another impact of the high level of contact with the trial team is 
potentially the Hawthorne effect, which has been suggested should be broadened to 
“research participant effect”(38), where the persistent interaction and completion of study 
activities can alter perception of symptoms. Overall, the level of interaction with the trial 
team meant that the placebo arm did not represent usual care. A future trial would ideally 
have less interaction between the trial team and participants, or would vary the investigator 
meeting participants.  
  
We have shown that a multi-centre trial of methlyphenidate for SAF is feasible but 
modification of the design is required to improve delivery; intensive safety monitoring is not 
required. A parallel-arm design is appropriate whereas a cross-over study would introduce 
unblinding.  A definitive trial is warranted given the lack of treatments for this common 
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Supplementary file 1 (S1) – Focus group outcomes relating to the FaST-MP study; 
description of participants in the post-trial focus groups, their views regarding aspects of the 
study design, and suggestions regarding changes in future studies. 
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Alcohol intake (units/week) 5.3 (7.6) 4.7 (10.3) 
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Figure 1 - Recruitment and screening (CONSORT statement) 
 
  
Excluded      329 
   Not fatigued    216 
   Not stable disease   38 
   Cardiac disease   32 
   Contraindicated medication  13 
   Alternative cause for fatigue  11 
   Seizures    6 
   Liver disease    3 
   Glaucoma    2 
   Thyroid disease   1 
   Unable to give informed consent  1 
   Unconfirmed diagnosis   1 
   Pregnant    1 
   Prior adverse reaction to stimulant 1 
   Psychiatric disease   1 
   Pulmonary hypertension  1 
   End stage renal failure   1 
Enrolment 
Declined     19 
   Side effect profile   4 
   Too many visits   4 
   Perceived fatigue not severe enough 3 
   Moving away    3 
   Considering pregnancy   2 
   Did not give reason   2 
   Already received stimulant  1 
 
Unable to contact    14 
 
Assessed for eligibility (n= 385) 
- Under NNUH Care = 379 
- Referral from other centre = 6 
Approached (n= 56) 
Randomised (n= 23) 
Allocated to methylphenidate  (n=15) 
Received allocated intervention  (n=15) 
Did not receive methylphenidate (n=0) 
Allocated to placebo   (n= 8) 
Received placebo    (n= 7) 
Did not receive placebo: 
Breached exclusion criteria   (n=1) 
Analysed     (n=7) 
Excluded from analysis 





Completed 12-week visit  (n=7) 
   - Final visit truncated at 12 weeks (n=1) 
Completed 18-week visit  (n=6) 
   - Final visit truncated at 18 weeks (n=0) 
Completed 24-week visit  (n=6) 
Lost to follow-up   (n=0) 
Post-trial questionnaires returned (n=7) 
Analysed     (n= 15) 
Excluded from analysis   (n= 0) 
Completed 12-week visit   (n=15) 
   - Final visit truncated at 12 weeks  (n=10) 
Completed 18-week visit   (n=11) 
   - Final visit truncated at 18 weeks  (n=1) 
Completed 24-week visit   (n=10) 
Lost to follow-up    (n=0) 
Post-trial questionnaires returned  (n=13) 
Allocation, follow-
up and analysis 
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Table 2 – Adverse event rates by treatment allocation; number of participants in each arm 
developing at least one AE within each individual organ system. 
CTCAE System Class 
Methylphenidate 
Number of participants 
with ≥1 event (%) 
Placebo 
Number of participants 
with ≥1 event (%) 
Ear and labyrinth  2 (13.3) 0 
Eye  1 (6.7) 3 (42.9) 
Gastrointestinal  7 (46.7) 1 (14.3) 
General disorders  2 (13.3) 2 (28.6) 
Infections and infestations 1 (6.7) 1 (14.3) 
Investigations 2(13.3) 0 
Metabolism and nutrition  1 (6.7) 0 
Musculoskeletal  5 (33.3) 1 (14.3) 
Nervous system  10 (66.7) 3 (42.9) 
Psychiatric  5 (33.3) 3 (42.9) 
Respiratory 7 (46.7) 6 (85.7) 
Reproductive system and breast  1 (6.7) 0 
Skin and subcutaneous tissue  4 (26.7) 1 (14.3) 
Vascular disorders 2 (13.3) 0 
Any 14 (93.3) 7 (100.0) 






Table 3 – Completion rates for questionnaires and other outcomes performed during the 
study 
 
Outcome Expected data points - n Missing Data points - n (%) 
FAS 165 2 (1.2) 
FACIT-Fatigue 165 2 (1.2) 
HADS 121 4 (3.3) 
KSQ 121 3 (2.5) 
EQ5D 121 3 (2.5) 
SF36 121 4 (3.3) 
Safety1 104 5 (4.8) 
PSQI2 43 2 (4.7) 
Spirometry (FEV1 and FVC)3 60 3 (5.0) 
MSWT4 60 7 (11.7) 
Activity monitor data5 60 3 (5.0) 
Total 1142 30 (2.6) 
 
Acronyms: FAS – Fatigue Assessment Scale; FACIT-Fatigue – Functional Assessment of Chronic Illness Therapy – 
Fatigue; HADS – Hospital Anxiety and Depression Scale; KSQ – Kings Sarcoidosis Questionnaire; EQ5D – 
EuroQoL 5 Dimension 5 Level scale; SF36 – Short Form 36; PSQI – Pittsburgh Sleep Quality Index; FEV1 – Forced 
Expiratory Volume in 1 second; MSWT – Modified shuttle walk test 
 
1Safety questionnaire was administered up to week 12; participants completing a truncated time period who 
completed study medications at week 12 did not all receive safety questionnaires at their final visit (4 out of 5 
missing data points). 
 
2PSQI only administered following major amendment approved in April 2017; expected data points refers to the 
number of visits where the questionnaire should have been administered after the study amendment was 
approved. 
 
3All missing spirometry values occurred in a single participant who was unable to perform the test without 
suffering syncope 
 
4Six of the seven missing MSWT values occurred due to loss of facilities to undertake the test 
 
5Missing data points for activity watches refers to an unreturned device (1 missing data point) or device not 






Figure 2 – Change in Fatigue Assessment Scale (A), Functional Assessment of Chronic Illness Therapy – Fatigue (B), Hospital Anxiety and 
Depression Scale – Anxiety (C) and – Depression (D) scores from baseline values over time, presented by allocation. Results are mean values 
with 95% confidence intervals.  
 
Number of participants per time-point: 
Methylphenidate: Weeks 0-12 – 15*; Week 18 – 11; Week 24 – 10    Placebo: Weeks 0-12 – 7*; Week 18 – 6; Week 24 – 6 
Week 30 time-point includes all data for participants returning data six-weeks after completing medications (n=13 for methylphenidate arm, n=7 for placebo arm**) 
Horizontal dotted line = Minimal clinically important difference. Lower scores indicate fewer problems for FAS and HADS. Higher scores indicate fewer problems for FACIT-F. 
*One missing data-point at week 6 for HADS-A and –D; **One missing data-point at week 30 for HADS-A and -D 
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